Vamil Divan
Stock Analyst at Guggenheim
(4.83)
# 92
Out of 5,238 analysts
253
Total ratings
68.62%
Success rate
22.19%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $230 → $226 | $101.35 | +122.99% | 9 | May 8, 2026 | |
| AMGN Amgen | Maintains: Neutral | $351 → $340 | $331.70 | +2.50% | 4 | May 4, 2026 | |
| ABBV AbbVie | Reiterates: Buy | $249 | $201.55 | +23.54% | 30 | May 1, 2026 | |
| TVTX Travere Therapeutics | Maintains: Buy | $54 → $56 | $42.60 | +31.46% | 10 | Apr 24, 2026 | |
| ASMB Assembly Biosciences | Maintains: Buy | $39 → $43 | $29.74 | +44.59% | 3 | Apr 6, 2026 | |
| UNCY Unicycive Therapeutics | Maintains: Buy | $46 → $40 | $7.94 | +403.78% | 2 | Apr 2, 2026 | |
| PFE Pfizer | Maintains: Buy | $35 → $36 | $25.68 | +40.19% | 24 | Mar 24, 2026 | |
| JBIO Jade Biosciences | Maintains: Buy | $17 → $23 | $25.81 | -10.89% | 3 | Mar 11, 2026 | |
| MRK Merck & Co. | Maintains: Buy | $122 → $140 | $111.38 | +25.70% | 15 | Feb 6, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $227 → $240 | $221.32 | +8.44% | 19 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $124 | $81.86 | +51.48% | 14 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $8 | $3.88 | +106.19% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $0.92 | +227.62% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $11 | $5.23 | +110.33% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $13 | $5.59 | +132.56% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $1.86 | +276.34% | 2 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $5.90 | +69.49% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $36.19 | +68.55% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $12.07 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $7.32 | +255.19% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.33 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $22.40 | -15.18% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $152.25 | -35.63% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $34.99 | -2.83% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.88 | +157.73% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $217.38 | -77.46% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $948.45 | -62.47% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $6.53 | -8.12% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $9.86 | +1,461.87% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $6.36 | +135.85% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $35.73 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $15.55 | -3.54% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $56.16 | +8.62% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $3.14 | +3,180.25% | 3 | Jan 17, 2018 |
Insmed
May 8, 2026
Maintains: Buy
Price Target: $230 → $226
Current: $101.35
Upside: +122.99%
Amgen
May 4, 2026
Maintains: Neutral
Price Target: $351 → $340
Current: $331.70
Upside: +2.50%
AbbVie
May 1, 2026
Reiterates: Buy
Price Target: $249
Current: $201.55
Upside: +23.54%
Travere Therapeutics
Apr 24, 2026
Maintains: Buy
Price Target: $54 → $56
Current: $42.60
Upside: +31.46%
Assembly Biosciences
Apr 6, 2026
Maintains: Buy
Price Target: $39 → $43
Current: $29.74
Upside: +44.59%
Unicycive Therapeutics
Apr 2, 2026
Maintains: Buy
Price Target: $46 → $40
Current: $7.94
Upside: +403.78%
Pfizer
Mar 24, 2026
Maintains: Buy
Price Target: $35 → $36
Current: $25.68
Upside: +40.19%
Jade Biosciences
Mar 11, 2026
Maintains: Buy
Price Target: $17 → $23
Current: $25.81
Upside: -10.89%
Merck & Co.
Feb 6, 2026
Maintains: Buy
Price Target: $122 → $140
Current: $111.38
Upside: +25.70%
Johnson & Johnson
Jan 23, 2026
Maintains: Buy
Price Target: $227 → $240
Current: $221.32
Upside: +8.44%
Jan 16, 2026
Maintains: Buy
Price Target: $115 → $124
Current: $81.86
Upside: +51.48%
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $3.88
Upside: +106.19%
Oct 28, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.92
Upside: +227.62%
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $5.23
Upside: +110.33%
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $5.59
Upside: +132.56%
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $1.86
Upside: +276.34%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $5.90
Upside: +69.49%
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $36.19
Upside: +68.55%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $12.07
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $7.32
Upside: +255.19%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.33
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $22.40
Upside: -15.18%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $152.25
Upside: -35.63%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $34.99
Upside: -2.83%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $3.88
Upside: +157.73%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $217.38
Upside: -77.46%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $948.45
Upside: -62.47%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $6.53
Upside: -8.12%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $9.86
Upside: +1,461.87%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $6.36
Upside: +135.85%
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $35.73
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $15.55
Upside: -3.54%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $56.16
Upside: +8.62%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $3.14
Upside: +3,180.25%